Login to Your Account



Pipeline Drugs Lining Up To Compete In Major PAH Market

By Randall Osborne


Monday, April 4, 2005

A spate of news at the start of this year regarding therapies for pulmonary arterial hypertension (PAH) threw fresh light on the disorder - and might put eventual pressure on the Swiss firm Actelion Ltd., which markets the only approved oral therapy: Tracleer (bosentan), the dual endothelin receptor antagonist given market clearance by the FDA in 2001.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription